Gaudium IVF and Women Health Limited GAUDIUMIVFshare price and chart
Gaudium IVF and Women Health closed at ₹99.44 on 19 November 2026, up 2.09% on the day. The range since listing is ₹69.18 to ₹163.18.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on GAUDIUMIVF
Real prices, every charge counted. Pick one or write your own.Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 19 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Healthcare Service Provider · 15 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 12 Nov 2026), sales was ₹37.4 cr and profit was ₹9.4 cr.
- Foreign institutions cut their holding by 8.1 points over 2 quarters (9.24% to 1.19%).
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Share price reaction to resultsWhat the share price did around each recent quarterly result.
Over the last 3 results, the share rose on 0 and fell on 3, and moved by 3% or more on 1.
Q2 FY27: results filed 12 Nov 2026. The share went from its close on 11 Nov 2026 to its close on 13 Nov 2026 -3.76%.
Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 4 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Healthcare Service Provider. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash rose by ₹2 Cr, after ₹2 Cr spent on plant and equipment.
The full numbersSales and net profit by financial year or by quarter.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Healthcare Service Provider| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB Dr. Lal Path Labs Ltd. | 32,952 cr | 56.2x | 12.0x | 21.5% | 29.1% | 0.00 | 19.4% | +19.6% | 0.89% |
| VIJAYA Vijaya Diagnostic Centre Limited | 15,559 cr | 76.3x | 14.7x | 19.7% | 30.3% | 0.00 | 22.4% | +26.7% | 0.13% |
| METROPOLIS Metropolis Healthcare Limited | 11,587 cr | 51.6x | 7.1x | 13.4% | 19.6% | 0.01 | 12.7% | +15.8% | 0.36% |
| THYROCARE Thyrocare Technologies Limited | 8,035 cr | 56.1x | 14.5x | 28.7% | 37.8% | 0.00 | 15.4% | +25.1% | 1.39% |
| NEPHROPLUS Nephrocare Health Services Limited | 6,455 cr | 49.4x | 5.4x | 6.9% | 13.4% | 0.07 | 11.5% | - | 0.00% |
| SURAKSHA Suraksha Diagnostic Limited | 1,718 cr | 41.1x | 6.2x | 13.8% | 24.8% | 0.02 | 11.9% | +25.8% | 0.15% |
| KRSNAA Krsnaa Diagnostics Limited | 1,673 cr | 17.0x | 1.6x | 10.9% | 12.7% | 0.57 | 11.1% | +31.5% | 0.39% |
| 3BBLACKBIO 3B Blackbio Dx Limited | 1,130 cr | 19.1x | - | - | - | - | 35.4% | +42.4% | 0.38% |
| HEALTHX Health X Platform Limited | 867 cr | - | 1.4x | -0.2% | - | 0.04 | -1.4% | +60.7% | 0.00% |
| CREDENT Credent Connect N Care Limited | 860 cr | - | 6.1x | - | - | 0.15 | - | - | 0.00% |
| ONEGLOBAL One Global Service Provider Limited | 749 cr | 12.0x | - | - | - | - | 14.1% | -50.8% | 0.26% |
| GAUDIUMIVF Gaudium IVF and Women Health Limited | 724 cr | 28.7x | 4.4x | 16.1% | 20.4% | 0.03 | 20.8% | - | 0.00% |
| CHANDAN Chandan Healthcare Limited | 599 cr | - | 3.5x | - | 22.4% | 0.32 | - | - | 0.00% |
| PRAMODINI Pramodini Medicare Limited | 230 cr | - | 2.0x | - | - | 0.26 | - | - | 0.00% |
| INVICTA Invicta Diagnostic Limited | 97 cr | - | 1.7x | - | - | 0.02 | - | - | 0.00% |
| NIDAN Nidan Laboratories and Healthcare Limited | 18 cr | 14.8x | 0.3x | - | 5.5% | 0.17 | 4.8% | -8.4% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | -10.9 | +69.8 | -3.7 | -3.4 | +21.7 | -7.0 | -13.0 | -4.8 | -6.1 | · | +23.9% 9m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2026-11-11 | KISHAN GOPAL MOHTA · bulk | SELL | 4,23,447 | ₹109.02 | ₹4.62 Cr |
| 2026-04-09 | GDN VENTURES LLP · bulk | BUY | 10,00,000 | ₹85.84 | ₹8.58 Cr |
| 2026-03-02 | KISHAN GOPAL MOHTA · bulk | BUY | 7,00,000 | ₹82.01 | ₹5.74 Cr |
| 2026-02-27 | PARAM CAPITAL · bulk | BUY | 25,00,000 | ₹85.51 | ₹21.38 Cr |
| 2026-02-27 | GDN INVESTMENTS PRIVATE LIMITED · bulk | BUY | 20,00,000 | ₹83.30 | ₹16.66 Cr |
| 2026-02-27 | NEOMILE INDIA OPPORTUNITY FUND · bulk | SELL | 15,76,910 | ₹84.89 | ₹13.39 Cr |
| 2026-02-27 | MINERVA EMERGING OPPORTUNITIES FUND LIMITED · bulk | SELL | 10,00,000 | ₹83.00 | ₹8.30 Cr |
- Press releasePress Release12 Nov 2026
Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated November 12, 2026, titled "Press Release on Unaudited Financial Results for the quarter and half year ended September 30, 2026."
- Board outcomeOutcome of Board Meeting12 Nov 2026
Gaudium IVF and Women Health Limited has submitted to the Exchange, the Unaudited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2026
- Press releasePress Release13 Aug 2026
Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated August 13, 2026, titled "press release on Unaudited Standalone and Consolidated Financial Results for the quarter June 30, 2026.".
- Board outcomeOutcome of Board Meeting13 Aug 2026
Gaudium IVF and Women Health Limited has submitted to the Exchange, the Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2026
- Press releasePress Release29 May 2026
Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release on Audited Financial Results for the quarter and year March 31, 2026.
- Board outcomeOutcome of Board Meeting28 May 2026
Gaudium IVF and Women Health Limited has submitted to the Exchange, the financial results for the quarter and year ended March 31, 2026.
- Press releasePress Release19 Mar 2026
Gaudium IVF and Women Health Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Gaudium IVF and Women Health Limited Announces Q3 & 9M FY26 Financial Results".
- Board outcomeOutcome of Board Meeting18 Mar 2026
Gaudium IVF and Women Health Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test GAUDIUMIVF. “Buy GAUDIUMIVF when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free